2+ day, 1+ hour ago   (689+ words) What is the biggest takeaway for clinicians from the CagriSema data presented at the 2026 ADA Scientific Sessions? How does amylin complement GLP-1 therapy, and why is that combination generating so much interest? As natural hormones, the GLP-1 and amylin are…...

2+ day, 1+ hour ago   (427+ words) The following transcript has been edited for clarity. Can you elaborate a little on what the results tell us about survodutide’s unique dual glucagon/GLP-1 mechanism? Dr. Le Roux: Yeah, because survodutide acts like an oxyntomodulin analog, a natural gut…...

1+ mon, 6+ day ago   (694+ words) Docwire News Methotrexate Lab Monitoring Frequency: How Much Is Actually Necessary? Methotrexate (MTX) is considered the cornerstone of therapy for rheumatoid arthritis and is widely used to treat other systemic rheumatic diseases as well, including systemic lupus, psoriatic arthritis, and…...

1+ mon, 1+ week ago   (213+ words) A phase 2 trial of the melanocortin-4 receptor agonist setmelanotide in patients with acquired hypothalamic obesity (aHO) showed evidence of substantial weight loss. However, further research is still needed to understand the safety and efficacy of the drug. In a phase…...

2+ mon, 1+ week ago   (384+ words) Dr. Nicholls: Well, I think we’re trying to understand the benefits of these agents across a whole range of different end organ complications. So I think in the setting of diabetes, it’s more than just improving glycemic control. We know…...

2+ mon, 3+ week ago   (134+ words) Cagrilintide-Semaglutide Could Improve Glycemic Control in Type 2 Diabetes Patients Taking Basal Insulin Participants were randomized to receive either once weekly subcutaneous cagrilintide plus semaglutide at either 2.4 mg (n=90) or 1.0 mg each (n=93), or a dose-matched placebo (pooled; n=91), which was…...

2+ mon, 3+ week ago   (272+ words) Globally, glomerulonephritis (GN) is a leading cause of kidney damage and kidney failure. Previous studies have found a renoprotective benefit associated with finerenone in individuals with type 2 diabetes and in those with CKD without diabetes. However, few findings shed light…...

2+ mon, 3+ week ago   (393+ words) Charanpreet Sasan, MD, from the University of Massachusetts Chan Medical School in Worcester, Massachusetts, shares results from a study comparing the use of GLP-1 receptor agonists and metabolic-bariatric surgery for cirrhosis complications and liver transplant outcomes. Charanpreet Sasan, MD: Hi, my…...

3+ mon, 1+ week ago   (220+ words) The primary outcome of interest was the incidence of dementia, Alzheimer’s disease, vascular dementia, frontotemporal dementia, Parkinson’s disease, extrapyramidal and movement disorders, and dementia with Lewy bodies. Follow-up ranged from 90 days to 5 years. The researchers used Kaplan-Meier survival curves and…...

3+ mon, 2+ week ago   (167+ words) The analysis compared kidney function in patients who achieved CR by week 36 (CR36) or any time up to week 110 (CR110) with that in patients who did not achieve CR (non-CR), regardless of original treatment allocation. Compared with non-CR patients, CR110 patients were more…...